Medical Developments International Ltd (ASX: MVP) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Medical Developments International Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $72.10 million
P/E Ratio 1,000.00
Dividend Yield 0.00%
Shares Outstanding 112.66 million
Earnings per share -0.336
Dividend per share 0.04
Year To Date Return 58.02%
Earnings Yield 0.10%
Franking 100%
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

Medical Developments International Ltd (ASX: MVP)
Latest News

a woman
Index investing

Is it time to buy Vanguard Australian Share ETF?

Is this a good time to buy Vanguard Australian Share ETF (ASX:VAS) which is focused on the ASX 300 (ASX:XKO)?

Read more »

a woman
Healthcare Shares

2 ASX biotech shares that could be the next CSL

Here are 2 ASX biotech shares that share similar characteristics to CSL and could potentially become the next biotech giants.

Read more »

a woman
Coronavirus News

Here's why analysts rate this ASX biotech share a 'buy'

This ASX biotech stock has fallen more than 50% since mid-Febraury, here's why analysts think its a great value buy.

Read more »

a woman
TMF AMP

Top ASX Stock Picks for April 2020

We asked our Foolish writers to pick their favourite ASX stocks to buy in April 2020. Here is what they…

Read more »

a woman
Share Gainers

This small cap ASX healthcare share is racing higher following a coronavirus update

The Medical Developments International Ltd (ASX:MVP) share price is racing higher today after providing an update on the impact of…

Read more »

a woman
Share Market News

Why this ASX healthcare share has risen over 200% in the past year

The Opthea Ltd (ASX: OPT) share price is up more than 200% in the past year. Here we take a…

Read more »

a woman
Share Market News

Is now the time to buy ASX biotech shares?

As we turn to biotech companies for a solution to halt the coronavirus, here are 2 ASX biotech shares to…

Read more »

a woman
Share Fallers

Medical Developments International share price lower on shock CEO exit

The Medical Developments International Ltd (ASX:MVP) share price is tumbling lower after announcing the shock exit of its CEO...

Read more »

a woman
Share Market News

What do P/E ratios really mean? And do they matter?

Let's simplify and explain the ubiquitous price to rarnings ratio and more importantly, its significance to you as an ASX…

Read more »

a woman
Share Market News

Why are Medical Developments shares crashing 11% lower today?

The Medical Developments International Ltd (ASX: MVP) share price is crashing lower on a day of sharp falls across most…

Read more »

a woman
Share Market News

Medical Developments shares move higher on strong earnings release

The Medical Developments International Ltd (ASX: MVP) share price is on the move today following the release of its half-year…

Read more »

a woman
Share Market News

3 ASX healthcare growth shares to add to your 2020 watchlist

Here are 3 companies that, while still speculative and risky in nature, have the potential to grow into tomorrow’s ASX…

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
05 Mar 2020 $0.0200 100.00% Interim 17 Apr 2020
03 Sep 2019 $0.0200 100.00% Final 04 Oct 2019
07 Mar 2019 $0.0200 100.00% Interim 17 Apr 2019
30 Aug 2018 $0.0200 100.00% Final 05 Oct 2018
02 Mar 2018 $0.0200 100.00% Interim 13 Apr 2018
31 Aug 2017 $0.0000 100.00% Final 06 Oct 2017
03 Mar 2017 $0.0200 100.00% Interim 10 Apr 2017
01 Sep 2016 $0.0200 100.00% Final 07 Oct 2016
02 Mar 2016 $0.0200 100.00% Interim 08 Apr 2016
02 Sep 2013 $0.0200 100.00% Final 11 Oct 2013
27 Feb 2013 $0.0300 100.00% Interim 11 Apr 2013
28 Feb 2012 $0.0300 100.00% Interim 11 Apr 2012
31 Aug 2011 $0.0300 100.00% Final 10 Oct 2011

MVP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Medical Developments International Ltd

Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.

The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries. 

 

 

MVP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
09 May 2025 $0.64 $0.02 3.23% 116,752 $0.62 $0.65 $0.62
08 May 2025 $0.62 $0.00 0.00% 25,734 $0.61 $0.62 $0.61
07 May 2025 $0.62 $0.00 0.00% 157,502 $0.63 $0.63 $0.59
06 May 2025 $0.62 $0.01 1.63% 161,994 $0.61 $0.63 $0.59
05 May 2025 $0.62 $-0.03 -4.69% 159,031 $0.63 $0.67 $0.60
02 May 2025 $0.64 $0.07 12.28% 324,457 $0.60 $0.65 $0.59
01 May 2025 $0.57 $-0.03 -5.00% 259,972 $0.60 $0.62 $0.56
30 Apr 2025 $0.60 $-0.01 -1.64% 645,492 $0.62 $0.64 $0.53
29 Apr 2025 $0.61 $0.15 32.26% 1,485,471 $0.51 $0.74 $0.51
28 Apr 2025 $0.47 $0.01 2.20% 226,188 $0.45 $0.50 $0.45
24 Apr 2025 $0.46 $0.00 0.00% 72,902 $0.45 $0.47 $0.43
23 Apr 2025 $0.46 $0.03 7.06% 132,243 $0.43 $0.46 $0.43
22 Apr 2025 $0.43 $-0.03 -6.67% 183,746 $0.45 $0.45 $0.42
17 Apr 2025 $0.45 $-0.02 -4.30% 97,423 $0.47 $0.48 $0.45
16 Apr 2025 $0.47 $-0.02 -4.12% 55,648 $0.49 $0.49 $0.47
15 Apr 2025 $0.49 $0.01 2.08% 116,522 $0.49 $0.51 $0.46
14 Apr 2025 $0.48 $-0.02 -4.00% 147,097 $0.48 $0.48 $0.45
11 Apr 2025 $0.50 $0.03 6.32% 33,423 $0.46 $0.50 $0.46
10 Apr 2025 $0.48 $0.02 4.40% 246,964 $0.47 $0.52 $0.46

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
28 Aug 2024 Christine Emmanuel-Donnelly Buy 26,478 $10,061
As advised by the company. Participation in capital Raise
28 Aug 2024 Gordon Naylor Issued 264,782 $100,617
Rights issue.
06 Aug 2024 Leon Hoare Buy 8,436 $3,205
As advised by the company. Participation in capital Raise
06 Aug 2024 Richard Betts Buy 3,181 $1,208
As advised by the company. Participation in capital Raise
06 Aug 2024 Maria (Mary) Sontrop Buy 2,801 $1,064
As advised by the company. Participation in capital Raise
06 Aug 2024 Christine Emmanuel-Donnelly Buy 7,684 $2,919
As advised by the company. Participation in capital Raise
06 Aug 2024 Gordon Naylor Buy 93,453 $35,512
As advised by the company. Participation in capital Raise
06 Aug 2024 Russell Basser Buy 2,160 $820
As advised by the company. Participation in capital Raise

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Leon Hoare Non-Executive Director Sep 2013
Mr Hoare is a commercial leader with expertise across multiple Life Science sectors. Previously, he was Managing Director of Smith & Nephew (S&N) ANZ, one of S&N's largest global subsidiaries outside the USA. He served as President of S&N's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division (as one of three Regional Presidents). In his 24 years with S&N, he also held roles in marketing, divisional and general management. His career has also included a senior role at Bristol-Myers Squibb, and as Vice-Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the Chair of the Human Resources Committee. He is member of Human Resource Committee.
Mr Richard Betts Non-Executive Director May 2021
Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 25 years. He was previously Chief Financial Officer at Pact Group Holdings Ltd for 6 years. Prior to that he held executive finance and general management roles at Orica Limited. These roles provided Mr Betts with a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has financial and governance experience within international manufacturing environments. Mr Betts is Chair of the Risk and Continuous Disclosure Committee.
Ms Christine Emmanuel-Donnelly Non-Executive Director May 2020
Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. Ms Emmanuel-Donnelly is a former Executive Manager of Business Development and Commercial at the CSIRO, where she led the management of CSIRO's IP team and IP portfolio for 14 years and managed the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel-Donnelly was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK), Davies Collison Cave and Griffith Hack in Melbourne. She is member of Risk Committee.
Mr Gordon Naylor Non-Executive DirectorNon-Executive Chairman Oct 2020
Mr Naylor for over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. He is member of Human Resource and Continuous Disclosure Committee.
Dr Russell Basser Non-Executive Director Aug 2023
Dr Basser is a physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has expertise in international drug and vaccine development and spent several years based in the USA. He is member of Human Resource Committee.
Mr Mark Fladrich Non-Executive Director Apr 2025
Mr Fladrich brings experience to MVP with over 30 years in the pharmaceutical industry. His background includes senior leadership roles at global companies. During his executive career, Mark was most recently Chief Commercial Officer of Grunenthal, a mid-sized privately owned German company specialising in pain management.In his 23 years at AstraZeneca, Mark held several senior roles including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Prior to joining AstraZeneca, Mark held various roles at Allergan (now part of AbbVie Inc) and Faulding Pharmaceuticals in Australia. Mark is the Chair of QBiotics, an Australian public unlisted life sciences company. Mark is also a Board Observer and Strategic Advisor at HealthMatch, a Sydney based digital startup matching patients with clinical trials, and Chair of the Strategic Advisory Board for Atacana, a global pharmaceutical and biotech industry consulting firm.
Mr Brent MacGregor Chief Executive Officer Nov 2020
-
Ms Tara Eaton Company SecretaryGeneral Counsel Aug 2022
-
A James CFO
-
Brent MacGregor Chief Executive Officer
-
Tara Eaton Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 10,683,815 9.48%
Citicorp Nominees Pty Limited 7,576,013 6.72%
HSBC Custody Nominees (Australia) Limited 6,500,532 5.77%
Lawn Views Pty Ltd <Angela Williams Family A/C> 5,904,120 5.24%
Moggs Creek Pty Ltd <Moggs Creek Super A/C> 5,278,615 4.69%
Ubs Nominees Pty Ltd 4,920,177 4.37%
Netwealth Investments Limited <Wrap Services A/C> 3,650,550 3.24%
Payne Media Pty Ltd 2,937,127 2.61%
Mirrabooka Investments Limited 2,592,084 2.30%
Dr Russell Kay Hancock 2,120,000 1.88%
HSBC Custody Nominees (Australia) Limited A/C 2 1,367,424 1.21%
BNP Paribas Nominees Pty Ltd <Clearstream> 1,364,260 1.21%
Naylor Stewart Investments Pty Ltd <Naylor Stewart Family A/C> 1,045,113 0.93%
Kidder Peabody Pty Ltd 1,042,945 0.93%
Merrill Lynch (Australia) Nominees Pty Limited 867,848 0.77%
Mr David Williams <William Street A/C> 861,817 0.76%
Neweconomy Com Au Nominees Pty Limited <900 Account> 861,039 0.76%
Mr Alistair David Strong 750,000 0.67%
National Nominees Limited 748,009 0.66%
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 733,300 0.65%

Profile

since

Note